These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26503656)

  • 1. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
    Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
    Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Regimens Containing TBI-166, a New Drug Candidate against
    Zhang Y; Zhu H; Fu L; Wang B; Guo S; Chen X; Liu Z; Huang H; Yang T; Lu Y
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
    Li S-Y; Tyagi S; Soni H; Betoudji F; Converse PJ; Mdluli K; Upton AM; Fotouhi N; Barros-Aguirre D; Ballell L; Jimenez-Navarro E; Nuermberger EL
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0156223. PubMed ID: 38376228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.
    Walter K; Te Brake LHM; Lemm AK; Hoelscher M; Svensson EM; Hölscher C; Heinrich N
    J Antimicrob Chemother; 2024 Oct; 79(10):2607-2610. PubMed ID: 39110473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
    Lyons MA; Obregon-Henao A; Ramey ME; Bauman AA; Pauly S; Rossmassler K; Reid J; Karger B; Walter ND; Robertson GT
    Antimicrob Agents Chemother; 2024 May; 68(5):e0101023. PubMed ID: 38501805
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
    Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.